Drug Patent Expirations in June 2012

Drug Patent Expirations in June 2012

*Drugs may be covered by multiple patents

Tradename Applicant Generic Name Patent Number Patent Expiration
IONSYS Incline Therap fentanyl hydrochloride 6,317,629 Jun 2, 2012
SULAR Shionogi Inc nisoldipine 5,422,123 Jun 6, 2012
REQUIP XL Smithkline Beecham ropinirole hydrochloride 5,422,123 Jun 6, 2012
ZYFLO CR Cornerstone Therap zileuton 5,422,123 Jun 6, 2012
DILACOR XR Watson Labs diltiazem hydrochloride 5,422,123 Jun 6, 2012
VIGAMOX Alcon Pharms Ltd moxifloxacin hydrochloride 4,990,517*PED Jun 8, 2012
MOXEZA Alcon Pharms Ltd moxifloxacin hydrochloride 4,990,517*PED Jun 8, 2012
IMITREX Glaxosmithkline sumatriptan 5,705,520*PED Jun 10, 2012
LESCOL Novartis fluvastatin sodium 5,356,896*PED Jun 12, 2012
LESCOL XL Novartis fluvastatin sodium 5,356,896*PED Jun 12, 2012
TRIZIVIR Viiv Hlthcare abacavir sulfate; lamivudine; zidovudine 5,034,394*PED Jun 18, 2012
EPZICOM Viiv Hlthcare abacavir sulfate; lamivudine 5,034,394*PED Jun 18, 2012
ZIAGEN Viiv Hlthcare abacavir sulfate 5,034,394*PED Jun 18, 2012
CHILDREN’S MOTRIN Mcneil Cons ibuprofen 5,374,659*PED Jun 20, 2012
MOTRIN Mcneil Consumer ibuprofen 5,374,659*PED Jun 20, 2012
CHILDREN’S MOTRIN Mcneil ibuprofen 5,374,659*PED Jun 20, 2012
EDARBYCLOR Takeda Pharms azilsartan kamedoxomil; chlorthalidone 5,736,555 Jun 25, 2012
NEORAL Novartis cyclosporine 6,258,808 Jun 25, 2012
EDARBI Takeda Pharms azilsartan kamedoxomil 5,736,555 Jun 25, 2012
NEORAL Novartis cyclosporine 6,262,022 Jun 25, 2012

 

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin. Courtesy of DrugPatentWatch.com


   No Comments yet


  1. Becky
      Jun 5, 2012

    In renewing the patents, is it the financial value of patenting process of each particular drugs varies or said to be much more higher from each another based on their sales data? like what if they are top selling drugs in the market that probably make more money when compare with others? and how about those drugs with multiple patents?

  2. Becky
      Jun 11, 2012

    well, now some kind of generics/or copied products now have the ability to be manufactured and produced by other company based on the procedure and information regarding the drugs. hence, products can go on sell and have a market to capture.

Leave a Reply